Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB160
- Development stage
- Unknown
- Lead developer
- Shanghai Euregen Biopharma
01
Overview
EB160: sourced facts only. name: "Here, we report the discovery of EB160, a novel, highly potent and brain-penetrant KRASG12C covalent inhibitor." [DOI:10.1158/1538-7445.am2022-5437]; target: "Here, we report the discovery of EB160, a novel, highly potent and brain-penetrant KRASG12C covalent inhibitor." [DOI:10.1158/1538-7445.am2022-5437]; developer: "1Shanghai Euregen Biopharma Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2022-5437]; stage: "In the H1373Luc KRASG12C brain metastases model, 30 mg/kg QD EB160 oral dose in mice for 28 days results in tumor regression 92%, while in the same dosage of MRTX849 treatment group, the tumor regression was 50%." [DOI:10.1158/1538-7445.am2022-5437]
02
Targets
Beyond the preview
Go deeper on EB160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB160.